Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative RC48, SOX, and Sintilimab for Locally Advanced Hepatoid Adenocarcinoma of Stomach
NCT06992362Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, sintilimab in Hepatoid adenocarcinoma of the stomach (HAS), sponsored by Peking University Cancer Hospital & Institute. Started May 2025; status: recruiting.
02
Drugs
disitamab vedotinsintilimab
03
Conditions
Hepatoid adenocarcinoma of the stomach (HAS)
Beyond the preview
Go deeper on NCT06992362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992362.